Erin Myers, PA
Medical · Roanoke, VANPI 1962737213
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,051 of the $13,752 with a category attached, or 87.6%. It is spread thinly across 47 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,383, 2.1 times the $2,072 reported in 2021. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 687 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amgen$916
- Abbott$875
- Dexcom, Inc.$867
- plus $7K from 41 others
What the payments were for
- Travel & lodging$1,70112%
- Food & beverage$12,05188%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$1,785
- TWIIST$150
- Senza$147
- Tymlos$142
- TZIELD$125
- t:slim X2 Insulin Pump with Control-IQ$112
- t-slim insulin pump$107
How this compares
$13,752 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 146 | $198,966 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 72 | $96,077 |
| MounjaroTirzepatide | 67 | $80,938 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $71,352 |
| Tresiba Flextouch U-100Insulin Degludec | 99 | $71,220 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 42 | $61,876 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 52 | $58,510 |
| JardianceEmpagliflozin | 39 | $56,283 |
| TrulicityDulaglutide | 35 | $44,733 |
| FarxigaDapagliflozin Propanediol | 35 | $39,107 |
| JanuviaSitagliptin Phosphate | 20 | $31,968 |
| RybelsusSemaglutide | 27 | $31,579 |
| FiaspInsulin Aspart (Niacinamide) | 25 | $26,644 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $26,494 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $22,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog | $1,253 | $332,478270 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Glyxambi | $299 | $141,253118 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,080 | $140,708148 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $262 | $96,07772 claims |
| AstraZenecaFarxiga | $437 | $39,10735 claims |
| MerckJanuvia | $41 | $31,96820 claims |
| AbbVieSynthroid | $283 | $10,932142 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $80 | $2,569304 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Roanoke
- Jason BaileyRoanoke$10K
- Dennis DuncanRoanoke$8K
- Lucia KulhavyRoanoke$6K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
- Christine KesslerKing George$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.